Transformed Lymphoma
14
6
6
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (14)
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
DALY II USA/ MB-CART2019.1 for DLBCL
POLA-R-CHP in the First-line Treatment of Transformed DLBCL
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma